Alectinib More Effective Compared to Current Standard of Care Crizotinib

Findings from a phase III clinical trial funded by funded by F. Hoffmann-La Roche, point to a more effective initial treatment for patients with...

Dacomitinib may Offer New Treatment Option for Patients with EGFR-Positive Lung...

Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive...

Single-dose Radiation Therapy may help Relieve Debilitating Spinal Cord Compression

A common complication in people with metastatic cancer, spinal cord compression or SCC, is a major detriment to Quality of Life (QoL). The symptoms...

Atezolizumab Shows Potential as Foundational Agent in the Treatment of Numerous...

Data for atezolizumab (Tecentriq®; Genentech/Roche) were presented during the 53rd annual meeting of the American Society of Clinical Oncology (ASCO), held June 2 - 6,...

Cancer Patients and Mental Health – a Focus at ASCO 2017

A diagnosis of advanced cancer weighs heavily on patients and families, and causes significant emotional distress. While doctors focus on addressing the health of...

Dramatic Progress in the Treatment of Childhood Cancers

Treatments for childhood cancer are often intense and carry an increased risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer...

Clinical trial of Novel Immune-based Therapy may Benefit Patients with Advanced...

While immune therapy has proven effective in treating certain types of cancer, especially lung cancer and melanoma, tumors of the pancreas remain among the...

Fat Storage may make Cancer Cells more Aggressive

It has been established that not all cancer cells are equally aggressive – most can be neutralized with radiation and chemotherapy. Researchers at Lund...

Positive Top Line Data Presented for Reolysin® in Randomized Phase III...

Initial positive top line data from the first endpoint in a double-blinded randomized Phase III clinical study examining Reolysin® (Reovirus Serotype 3 Dearing; Oncolytics),...

Latest